What is the clinical significance of an alanine aminotransferase (ALT) level of 37 U/L with a normal aspartate aminotransferase (AST), and how should this isolated elevation be evaluated?

ALT of 37 U/L with Normal AST: Clinical Significance

An ALT of 37 U/L with normal AST is likely within normal limits for most men but may represent mild elevation in women, and generally does not require urgent evaluation in the absence of other clinical concerns.

Understanding the Reference Range

The interpretation of this ALT value depends critically on sex-specific reference ranges, which are lower than traditional laboratory cutoffs:

• For men: Normal ALT is 29-33 IU/L 1, 2
• For women: Normal ALT is 19-25 IU/L 1, 2

Your ALT of 37 U/L represents:

• A mild elevation if you are male (approximately 1.1-1.3× the upper normal limit)
• A more notable elevation if you are female (approximately 1.5-1.9× the upper normal limit)

These updated reference ranges are significantly lower than commercial laboratory standards because older ranges inadvertently included patients with occult nonalcoholic fatty liver disease (NAFLD) 2, 3.

Clinical Significance

The isolated elevation of ALT without AST elevation suggests:

• Hepatocellular pattern of injury rather than cholestatic disease 1
• ALT is more liver-specific than AST, which can be elevated from cardiac, skeletal muscle, kidney, or red blood cell disorders 1
• The normal AST helps exclude non-hepatic causes and suggests any liver involvement is likely mild 4

Important context: The magnitude of ALT elevation does NOT necessarily correlate with disease severity 2, 3. Patients with significant liver disease, including advanced fibrosis, can have normal or minimally elevated ALT levels 5, 3.

Most Common Causes at This Level

For mild ALT elevations (<5× upper limit of normal), the most common etiologies are 1:

1. Nonalcoholic fatty liver disease (NAFLD) - prevalence 20-30% in general population, 70% with obesity, 90% with diabetes
2. Alcohol-related liver disease
3. Medications/supplements (including over-the-counter drugs, herbs, vitamins)
4. Chronic viral hepatitis B or C
5. Metabolic factors: obesity, insulin resistance, dyslipidemia

Recommended Evaluation Approach

Initial assessment should include:

• Metabolic risk factors: BMI, presence of diabetes, dyslipidemia, metabolic syndrome 2, 1
• Alcohol consumption history: quantify drinks per week 6
• Complete medication review: prescription drugs, over-the-counter medications, herbal supplements, vitamins 7, 8
• Risk factors for viral hepatitis: exposure history, risk behaviors 2

First-line testing if clinically indicated:

• Hepatitis B surface antigen (HBsAg) and hepatitis C antibody 5, 7
• Fasting glucose and lipid panel (if not recently done)
• Complete metabolic panel to assess other liver enzymes (alkaline phosphatase, bilirubin)
• Abdominal ultrasound to evaluate for hepatic steatosis 1

When to Pursue Further Workup

You can observe without immediate intervention if:

• No symptoms (fatigue, right upper quadrant pain, nausea)
• No risk factors for chronic liver disease
• Normal bilirubin, alkaline phosphatase, and synthetic function (albumin, INR)
• No clinical signs of chronic liver disease

Consider more extensive evaluation if:

• Age ≥35-40 years (higher risk of significant fibrosis) 2
• Persistent elevation on repeat testing over 6 months 7, 3
• Presence of metabolic risk factors (obesity, diabetes, dyslipidemia)
• Any symptoms suggestive of liver disease
• Family history of liver disease or hepatocellular carcinoma 2

Common Pitfalls to Avoid

1. Don't assume normal ALT excludes liver disease - significant fibrosis can exist with normal transaminases 5, 3

2. Don't rely solely on commercial laboratory "normal ranges" - these are often too high (sometimes >70 U/L) and miss early disease 6, 3

3. Don't ignore metabolic factors - ALT is affected by BMI, gender, insulin resistance, and fatty liver 2

4. Don't forget medication review - this includes ALL supplements, herbs, and over-the-counter products 7, 8

Monitoring Strategy

If initial evaluation is unrevealing and you elect observation:

• Repeat ALT in 3-6 months to establish trend 7, 3
• If persistently elevated, consider non-invasive fibrosis assessment (FIB-4 score, elastography) 5
• Address modifiable risk factors: weight loss if overweight, alcohol cessation, medication review 1

Bottom line: An ALT of 37 U/L with normal AST is a mild abnormality that warrants clinical correlation but typically does not require urgent intervention. The approach should be guided by sex, age, metabolic risk factors, and whether the elevation persists on repeat testing.